Protopapas Anna has filed 48 insider transactions across 2 companies since June 2023.
Most recent transaction: a transaction of 6721 shares of Mersana Therapeutics, Inc. ($MRSN) on January 06, 2026.
Activity breakdown: 0 open-market purchases and 5 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | U | Common Stock | 6721 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.13% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | U | Common Stock | 9609 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.19% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 2460 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.05% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 988 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 18 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.00% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 1 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.00% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 8137 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.16% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 542 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 7519 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.15% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 480 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 2500 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.05% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | U | Common Stock | 2890 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.06% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 166 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.00% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 5227 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.10% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 1131 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.02% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 2200 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.04% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 11250 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.23% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 9043 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.18% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 665 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.01% |
| Jan. 6, 2026 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | D | Stock Option (right to buy) | 11761 | $0.00 | 0.0000 | 4,998,750 | 100.00% | 0.24% |
| June 18, 2025 | Nuvalent, Inc. | $NUVL | Protopapas Anna | Not found | A | Class A Common Stock | 2647 | $0.00 | 5,146.0000 | 66,408,807 | 105.92% | 0.00% |
| June 18, 2025 | Nuvalent, Inc. | $NUVL | Protopapas Anna | Not found | A | Stock Option (Right to Buy) | 4147 | $0.00 | 4,147.0000 | 66,408,807 | 9999.99% | 0.01% |
| June 12, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | A | Stock Option (right to buy) | 61500 | $0.00 | 61,500.0000 | 124,631,339 | 9999.99% | 0.05% |
| Jan. 16, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | S | Common Stock | 8637 | $0.58 | 480,548.0000 | 0 | 1.77% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Restricted Stock Unit | 21250 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Common Stock | 21250 | $0.00 | 489,185.0000 | 0 | 4.54% | 0.00% |
| Jan. 14, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Common Stock | 16750 | $0.00 | 474,126.0000 | 0 | 3.66% | 0.00% |
| Jan. 15, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | S | Common Stock | 6191 | $0.63 | 467,935.0000 | 0 | 1.31% | 0.00% |
| Jan. 14, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Restricted Stock Unit | 16750 | $0.00 | 16,750.0000 | 0 | 50.00% | 0.00% |
| Jan. 14, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | S | Common Stock | 11534 | $0.66 | 457,376.0000 | 0 | 2.46% | 0.00% |
| Jan. 13, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Common Stock | 31250 | $0.00 | 468,910.0000 | 0 | 7.14% | 0.00% |
| Jan. 13, 2025 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Restricted Stock Unit | 31250 | $0.00 | 62,500.0000 | 0 | 33.33% | 0.00% |
| June 12, 2024 | Nuvalent, Inc. | $NUVL | Protopapas Anna | Not found | A | Stock Option (Right to Buy) | 3789 | $0.00 | 3,789.0000 | 58,223,339 | 9999.99% | 0.01% |
| June 12, 2024 | Nuvalent, Inc. | $NUVL | Protopapas Anna | Not found | A | Class A Common Stock | 2499 | $0.00 | 2,499.0000 | 58,223,339 | 9999.99% | 0.00% |
| June 11, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | A | Stock Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 14, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Restricted Stock Unit | 16750 | $0.00 | 33,500.0000 | 0 | 33.33% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Common Stock | 17708 | $0.00 | 467,059.0000 | 0 | 3.94% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Common Stock | 21250 | $0.00 | 449,351.0000 | 0 | 4.96% | 0.00% |
| Jan. 14, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Common Stock | 16750 | $0.00 | 428,101.0000 | 0 | 4.07% | 0.00% |
| Jan. 13, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Common Stock | 31250 | $0.00 | 411,351.0000 | 0 | 8.22% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Restricted Stock Unit | 17708 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 15, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Restricted Stock Unit | 21250 | $0.00 | 21,250.0000 | 0 | 50.00% | 0.00% |
| Jan. 13, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | M | Restricted Stock Unit | 31250 | $0.00 | 93,750.0000 | 0 | 25.00% | 0.00% |
| Jan. 16, 2024 | Mersana Therapeutics, Inc. | $MRSN | Protopapas Anna | Director | S | Common Stock | 29399 | $2.71 | 437,660.0000 | 0 | 6.29% | 0.00% |
| Dec. 18, 2023 | Nuvalent, Inc. | $NUVL | Protopapas Anna | Director | M | Class A Common Stock | 5000 | $9.36 | 5,000.0000 | 49,668,864 | 9999.99% | 0.01% |
| Dec. 18, 2023 | Nuvalent, Inc. | $NUVL | Protopapas Anna | Director | S | Class A Common Stock | 5000 | $75.67 | 0.0000 | 49,668,864 | 100.00% | 0.01% |
| Dec. 18, 2023 | Nuvalent, Inc. | $NUVL | Protopapas Anna | Director | M | Stock Option (Right to Buy) | 5000 | $0.00 | 15,000.0000 | 49,668,864 | 25.00% | 0.01% |
| June 15, 2023 | Nuvalent, Inc. | $NUVL | Protopapas Anna | Director | A | Stock Option (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 49,668,864 | 9999.99% | 0.03% |